Free Trial

OpGen Q3 2023 Earnings Report

OpGen logo
$0.76 -0.22 (-22.73%)
As of 03:46 PM Eastern

OpGen EPS Results

Actual EPS
-$4.60
Consensus EPS
-$4.30
Beat/Miss
Missed by -$0.30
One Year Ago EPS
N/A

OpGen Revenue Results

Actual Revenue
$0.70 million
Expected Revenue
$0.90 million
Beat/Miss
Missed by -$200.00 thousand
YoY Revenue Growth
N/A

OpGen Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

OpGen Earnings Headlines

StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)
StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)
Trump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out
This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth protection guide shows you how to use Trump's vision to lock down your savings—your freedom, your future. Plus, for a few lucky individuals, we're honoring Trump's historic return with an exclusive free gift.
OpGen Appoints New COO and Company Secretary
See More OpGen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OpGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OpGen and other key companies, straight to your email.

About OpGen

OpGen (NASDAQ:OPGN), a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

View OpGen Profile

More Earnings Resources from MarketBeat